Base-Free Synthesis of Tafamidis to Reduce Tetrachloroamide Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for producing Tafamidis and its meglumine salts are hindered by the generation of tetrachloroamide impurities due to the use of bases like triethylamine and pyridine, requiring tedious and solvent-consuming purification methods, which increase production costs and complexity.
Innovation Solution
Conducting the reaction of 4-amino-3-hydroxybenzoic acid with 3,5-dichlorobenzoyl chloride in the absence of a base to minimize tetrachloroamide impurity formation, and developing novel crystalline forms (Form-S, Form-N, Form-R) and an amorphous premix of Tafamidis meglumine with pharmaceutically acceptable excipients, along with improved processes for their preparation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If bases like triethylamine and pyridine are used in the reaction, then the reaction proceeds efficiently, but tetrachloroamide impurities are generated requiring tedious purification
Solution Approach 1:
The patent removes the base component (triethylamine or pyridine) from the reaction system entirely, replacing it with a base-free conditions using 3,5-dichlorobenzoyl chloride and 4-amino-3-hydroxybenzoic acid directly. This extraction of the harmful element (base) eliminates the source of tetrachloroamide impurity formation while maintaining reaction efficiency through direct coupling of the reactants.
Solution Approach 2:
Instead of using base to facilitate the reaction and then removing impurities, the patent inverts the approach by using base-free conditions from the start. The reaction is designed to proceed without base catalyst, and the solvent system (toluene/water or THF/water) is optimized to enable direct reaction and facilitate product isolation without base-related impurities.
2Manufacturing precision
If purification methods are applied to eliminate tetrachloroamide impurity, then purity is improved, but the process becomes solvent-consuming and time-consuming
Solution Approach 1:
The patent performs preliminary action by preventing impurity formation at the source through base-free reaction conditions. By designing the reaction to proceed without base, the tetrachloroamide impurity is never generated in the first place, eliminating the need for subsequent purification steps. The solvent system is pre-optimized to facilitate direct isolation of the pure intermediate compound.
Solution Approach 2:
The patent converts the potential harm of base-catalyzed side reactions into a benefit by deliberately using base-free conditions. This approach transforms what would be a problematic reaction pathway into a clean, impurity-free process. The solvent system (toluene/water or THF/water) acts as a benign medium that enables both reaction progression and easy product isolation without generating harmful byproducts.
3Manufacturing precision
If multiple purification steps are implemented, then impurity removal is effective, but production cost increases
Solution Approach 1:
The patent extracts the base component from the reaction system, which is the root cause of impurity formation. This single extraction eliminates the need for multiple purification steps, directly reducing production costs while maintaining high purity of the intermediate compound. The base-free conditions simplify the entire manufacturing process.
Solution Approach 2:
The patent discards the base catalyst approach entirely and recovers resources by using recyclable solvent systems (toluene/water or THF/water). The simplified process without base-related impurities reduces waste treatment requirements and allows for more efficient solvent recovery and reuse, thereby reducing overall production costs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The absence of bases during the reaction significantly reduces tetrachloroamide impurities, resulting in a more cost-effective and efficient production process that yields stable, high-purity crystalline and amorphous forms of Tafamidis suitable for industrial-scale pharmaceutical applications.
Implementation Method 1
reacting 4-amino-3-hydroxybenzoic acid with 3,5-dichlorobenzoyl chloride to provide 4-(3,5-dichlorobenzamido)-3-hydroxybenzoic acid
Implementation Method 2
The obtained compound was further cyclized to provide Tafamidis
Implementation Method 3
novel crystalline forms (Form-S, Form-N, Form-R) and an amorphous premix of Tafamidis meglumine
Data Source
AI summary
The present invention relates to process for the preparation of 2-(3,5-dichlorophenyl)-1,3- benzoxazole-6-carboxylic acid of formula (I), its pharmaceutically acceptable salts and polymorphs thereof which are used in the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.